Apomorphine inhalation - Vectura

Drug Profile

Apomorphine inhalation - Vectura

Alternative Names: VR 004; VR 040; VR 400

Latest Information Update: 06 Aug 2015

Price : $50

At a glance

  • Originator Vectura
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Erectile dysfunction; Female sexual dysfunction; Parkinson's disease

Most Recent Events

  • 01 Sep 2011 Apomorphine inhalation - Vectura is still available for licensing. http://www.vectura.com
  • 31 Mar 2011 Vectura completes a phase II trial in Parkinson's disease in the UK (EudraCT2005-005120-13)
  • 11 Jun 2010 Vectura's inhaled apomorphine product is still in Phase-II trials for Parkinson's disease in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top